We are live on ! Find out more
RNA

Atrium Therapeutics
RNA

162 hedge funds and large institutions have $198M invested in Atrium Therapeutics in 2026 Q1 according to their latest regulatory filings, with 162 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

86.6% more ownership

Funds ownership: 0% → 86.6% (+87%)

94% less call options, than puts

Call options by funds: $968K | Put options by funds: $15.6M

Holders
162
Holders Change
+162
Holders Change %
–
% of All Funds
1.99%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
162
Increased
–
Reduced
–
Closed
–
Calls
$968K
Puts
$15.6M
Net Calls
-$14.6M
Net Calls Change
-$14.6M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$21.8M
2
BlackRock
BlackRock
New York
+$16.9M
3
RCM
RA Capital Management
Massachusetts
+$12.1M
4
TAL
TIG Advisors LLC
New York
+$8.54M
5
PCM
Pentwater Capital Management
Florida
+$8.47M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WCMNY
51
Westchester Capital Management (New York)
New York
$739K +$776K +55,236 New
AIC
52
AWM Investment Company
New York
$669K +$703K +50,000 New
TS
53
Twin Securities
New York
$667K +$701K +49,913 New
UBS Group
54
UBS Group
Switzerland
$666K +$700K +49,814 New
OBAM
55
ODDO BHF Asset Management
France
$603K +$634K +45,090 New
CAU
56
Caxton Associates (UK)
$591K +$621K +44,230 New
ACM
57
Alethea Capital Management
Washington
$585K +$615K +43,758 New
Bank of New York Mellon
58
Bank of New York Mellon
New York
$584K +$614K +43,697 New
Canada Pension Plan Investment Board
59
Canada Pension Plan Investment Board
Ontario, Canada
$561K +$590K +41,970 New
HCM
60
Highbridge Capital Management
New York
$555K +$576K +40,986 New
SCM
61
Saba Capital Management
New York
$530K +$557K +39,640 New
FLC
62
Fifth Lane Capital
Texas
$481K +$506K +35,999 New
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$477K +$502K +35,698 New
KCM
64
Kennedy Capital Management
Missouri
$454K +$477K +33,977 New
Marshall Wace
65
Marshall Wace
United Kingdom
$450K +$473K +33,691 New
LP
66
LMR Partners
United Kingdom
$435K +$457K +32,500 New
BHCM
67
Brevan Howard Capital Management
Jersey
$423K +$445K +31,644 New
GLF
68
Groupe la Francaise
France
$397K +$417K +29,698 New
Fidelity Investments
69
Fidelity Investments
Massachusetts
$392K +$412K +29,292 New
WP
70
Woodline Partners
California
$386K +$405K +28,845 New
N
71
Nuveen
North Carolina
$338K +$356K +25,307 New
CGIM
72
Cannon Global Investment Management
Florida
$335K +$352K +25,087 New
CIEC
73
Crédit Industriel et Commercial
France
$308K +$323K +23,000 New
Point72 Asset Management
74
Point72 Asset Management
Connecticut
$304K +$319K +22,708 New
FIG
75
Fortress Investment Group
New York
$295K +$310K +22,033 New
1 2
3
4 5

RNA Hedge Fund Activity: Q1 2026 in Review

162 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Atrium Therapeutics (RNA) for Q1 2026, worth a combined $198M.

Buyers outnumbered sellers: 162 funds opened new RNA positions and 0 closed out — a net gain of 162 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $21.8M.

  • 162 institutional investors held Atrium Therapeutics (RNA) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $198M of Atrium Therapeutics stock for Q1 2026.
  • 162 funds opened new Atrium Therapeutics positions in Q1 2026 and 0 closed out, a net change of +162 holders.
  • The largest Atrium Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $21.8M added.

Based on aggregated 13F filings for Q1 2026.